Opus Genetics Announces $23 Million Direct Offering

Opus Genetics ( (IRD) ) just unveiled an announcement.

On November 6, 2025, Opus Genetics announced a $23 million registered direct offering to fund the development of its gene therapy programs, particularly for LCA5 and BEST-1. The company also reported the successful completion of a Type B RMAT meeting with the FDA for its OPGx-LCA5 gene therapy candidate, which showed promising results in Phase 1/2 trials. The FDA’s feedback will guide the Phase 3 study, expected to start dosing in the second half of 2026. The offering and FDA meeting position Opus Genetics to advance its mission of restoring vision in patients with inherited retinal diseases.

The most recent analyst rating on (IRD) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Opus Genetics stock, see the IRD Stock Forecast page.

Spark’s Take on IRD Stock

According to Spark, TipRanks’ AI Analyst, IRD is a Neutral.

Opus Genetics faces significant financial challenges, with declining revenues and persistent losses undermining its financial stability. The technical indicators suggest a bearish trend, while the negative corporate event further highlights financing difficulties. These factors contribute to a low overall score, indicating a high-risk investment with uncertain prospects.

To see Spark’s full report on IRD stock, click here.

More about Opus Genetics

Opus Genetics is a clinical-stage biopharmaceutical company based in Research Triangle Park, NC, focused on developing gene therapies for inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders. Its pipeline includes AAV-based gene therapies targeting conditions such as Leber congenital amaurosis, bestrophinopathy, and retinitis pigmentosa, with lead candidates OPGx-LCA5 and OPGx-BEST1.

Average Trading Volume: 374,207

Technical Sentiment Signal: Hold

Current Market Cap: $130M

Learn more about IRD stock on TipRanks’ Stock Analysis page.